*Bordetella pertussis* is a major etiological agent of pertussis (whooping cough). The disease can be atypical and pertussis-like coughing can be caused by other respiratory pathogens \[[@CR4]\]. The diagnosis of pertussis is usually suspected clinically, but only proven by specific polymerase chain reaction (PCR) or culture.

PCR methods are more sensitive for *B. pertussis* identification and other respiratory pathogens. Multiplex real-time PCR could be applied as broad-range respiratory PCR.

All patients in whom a diagnostic test for *B. pertussis* was requested from April 2001 to February 2002 were included. The records of the patients were analyzed retrospectively and the patients were assigned to two groups as described in Table [1](#Tab1){ref-type="table"} \[[@CR6]\]. Table 1Two groups of rettrospectively analyzed patients.WHO recommended case definitionClinical case definitionA case diagnosed as pertussis by a physician **or**A person with a cough lasting at least 2 weeks with at least one of the following symptoms:Paroxysms (i.e., fits) of coughingInspiratory whoopingPost-tussive vomiting (i.e., vomiting immediately after coughing) without other apparent causeCriteria for laboratory confirmationIsolation of *Bordetella pertussis* **or**Detection of genomic sequences by means of the PCRCase classification:Suspected: A case that meets the clinical case definition.Confirmed: A person with a cough that is laboratory-confirmed or epidemiologically linked to a laboratory confirmed case.Group I - Case that meets the definition for suspected pertussisGroup II - Case that does not meet the definition for suspected pertussis.

Nasopharyngeal swabs (15 samples), throat swabs (39 samples), sputum (three samples) and nasopharyngeal aspirates (NPAs) (five samples) were received. The PCR assay was performed by a single extraction. The extracted nucleic acid was thereafter added to a four-tube multiplex RNA real-time PCR for 11 RNA respiratory viruses \[[@CR4]\] and a four-tube DNA real-time PCR \[[@CR4], [@CR5]\]. All PCR products were detected by specific fluorophore-labelled probes that can be distinguished without post-PCR analysis.

Sixty-two patients were seen in the study period from which a diagnostic test for *B. pertussis* was requested. Sufficient clinical information could be obtained on 59/62 (95%) patients and assigned Group I or Group II. The clinical information for 59 patients is shown in Table [2](#Tab2){ref-type="table"}, the symptoms of paroxysmal cough and whoops were significantly associated with Group I. Table 2Clinical characteristics of patients in study group Pertussis^a^Non-pertussis^b^Whole group*P* ^c^(*n* = 38)(*n* = 21)(*n* = 59)Group IGroup II(%)Male16927NSAge  \<118 (13)10 (3)28NS1--1216826NS\>12438NSPertussis vaccination2518420.018Immunocompromised325NSStage of disease^d^ Catarrhal17926NS Paroxysmal12517NS Convalescent347NSClinical details^d^ Cough321850NS Paroxysmal26834\<0.005 Whoop5050.045 Vomiting16925NS Fever55110.014GP161228NSOut-patient clinic8412NSHospital admission14822NS^a^Patients that meet the clinical definition for suspected pertussis^b^Patients that did not meet the clinical definition for suspected pertussis^c^Statistical differences between Group I and Group II^d^Incomplete clinical details for six cases in the pertussis group and three cases in the non-pertussis group*Numbers in parentheses* indicate no pertussis vaccinationNo clinical information was available for three cases and these were not assigned to either group

Analysis of the samples by real-time PCR showed that *B. pertussis* was detected in 17 of the 38 patients in Group I and none of the patients in Group II (P \< 0.005). Using the WHO definition for suspected pertussis used in surveillance as the 'gold standard' for *B. pertussis*, the PCR has a sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of 45, 100, 100 and 48%, respectively. Other pathogens were detected in group I as shown in Table [3](#Tab3){ref-type="table"}. Some respiratory viruses were detected in Group II. All other respiratory pathogens had sensitivity and specificity lower than *B. pertussis.* Pathogens were detected by PCR in 31 out of 38 (82%) cases and 10 out of 21 (48%) cases in Group I and Group II, respectively. This difference was significant (p = 0.01). Table 3Pertussis-related symptoms in relation to pathogen detectedPathogensGroup I^a^ (*n* = 38)Group II^b^ (*n* = 21)*P* ^*c*^*Bordetella Pertussis*170\<0.005Other atypical bacteria^d^20NSHuman rhinoviruses164NSRespiratory syncytial virus150.02Parainfluenza viruses23NSAdenovirus61NSHuman coronavirus --229E10NSHuman metapneumovirus01NSMixed infections144NSNo infection7110.01^a^Patients that meet the clinical definition for suspected pertussis^b^Patients that did not meet the clinical definition for suspected pertussis^c^Statistical differences between Group I and Group II^d^ *Mycoplasma pneumoniae* (1) and *Chlamydophila pneumoniae* (1)No influenza A&B virus, human coronavirus OC43, *B. parapertussis* or *B. holmesii* were detected

Detection of *B. pertussis* by PCR was indicated on the basis of clinical presentation and PPV of 100% was obtained. However, 21 out of 38 cases that met the clinical definition of pertussis were negative for *B. pertussis*. Therefore, either the *B. pertussis* PCR gave false-negative results or the definition gave a false-positive result. Different sample types have different sensitivities, with NPAs being the most sensitive. PCR can also give false-negative results and fewer diagnoses in those patients with pertussis could be due to the quality of the sample.

Other pathogens were detected in 31 out of 38 patients with clinical diagnosis of pertussis. Other pathogens that cause a pertussis-like disease have previously been described using serological assays and Cherry et al. describe that pertussis can be misdiagnosed, as there are a number of viral and bacterial pathogens other than *B. pertussis* that can cause a paroxysmal cough \[[@CR1], [@CR2]\]. It has been well described that PCR is more sensitive than culture at detecting *B. pertussis* in the acute phase \[[@CR3]\]. The use of PCR for diagnosis would help improve microbiological diagnosis, improve the speed of results, and reduce the need for the reliance on imperfect clinical criteria for diagnosis. This would prompt more appropriate treatment of *B. pertussis* and other atypical bacteria, differentiating them from viral infections as well as use of vaccination to prevent spread of pertussis.

In conclusion, multiplex PCR in a combined approach identifies *B. pertussis* and other pathogens causing pertussis-like symptoms and use of this form of diagnosis might help in treatment and improve management of patients.
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